Cargando…
Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/ http://dx.doi.org/10.1186/2051-1426-3-S2-O9 |
| _version_ | 1782400830244126720 |
|---|---|
| author | Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F |
| author_facet | Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F |
| author_sort | Harvey, Christopher |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645516 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46455162015-11-20 Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F J Immunother Cancer Oral Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645516/ http://dx.doi.org/10.1186/2051-1426-3-S2-O9 Text en Copyright © 2015 Harvey et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Harvey, Christopher Elpek, Kutlu Duong, Ellen Simpson, Tyler Shu, ChengYi J Shallberg, Lindsey Wallace, Matthew Sathyanarayanan, Sriram Mabry, Robert Briskin, Michael Michaelson, Jennifer Gajewski, Thomas F Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| title | Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| title_full | Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| title_fullStr | Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| title_full_unstemmed | Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| title_short | Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| title_sort | efficacy of anti-icos agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/ http://dx.doi.org/10.1186/2051-1426-3-S2-O9 |
| work_keys_str_mv | AT harveychristopher efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT elpekkutlu efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT duongellen efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT simpsontyler efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT shuchengyij efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT shallberglindsey efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT wallacematthew efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT sathyanarayanansriram efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT mabryrobert efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT briskinmichael efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT michaelsonjennifer efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics AT gajewskithomasf efficacyofantiicosagonistmonoclonalantibodiesinpreclinicaltumormodelsprovidesarationaleforclinicaldevelopmentascancerimmunotherapeutics |